Health Care·Biotechnology·$14.2B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.35 | N/A | -19.47% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-1.35 | N/A | -19.47% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management acknowledged the challenges faced during the quarter. They emphasized their commitment to advancing their drug development programs.
Management did not provide specific guidance for the upcoming quarters.
The company is focusing on its pipeline and ongoing clinical trials.
The earnings report indicates that BridgeBio Pharma is still facing significant challenges, particularly reflected in their EPS miss. The stock's sharp decline of 12.47% suggests investor disappointment, likely due to the lack of revenue data and guidance. Moving forward, the company will need to focus on its clinical pipeline to regain investor confidence.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ENTERPRISE PRODS PAR
May 2, 2022